The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study

Autor: Sang-Cheol Bae, Damon L. Bass, Myron Chu, Paula Curtis, Richard Dimelow, Laurence Harvey, Beulah Ji, Regina Kurrasch, Saima Muzaffar, Raj Punwaney, David A. Roth, Yeong-Wook Song, Wendy Xie, Fengchun Zhang

Publikováno v: Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-11 (2022)

Abstract Background Treatment goals for patients with systemic lupus erythematosus (SLE) include minimising disease activity and reducing the risk of flares. Although belimumab is effective at reducing disease activity and risk of severe flares, it w

Externí odkaz: https://doaj.org/article/ff6acac1a96a455ebd7f0d19e3d58275

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus

Autor: Murray B. Urowitz, Cynthia Aranow, Yumi Asukai, Damon L. Bass, Ian N. Bruce, Deven Chauhan, Maria Dall'Era, Richard Furie, Norma Lynn Fox, Jennifer A. Gilbride, Anne Hammer, Ellen M. Ginzler, Tania Gonzalez‐Rivera, Roger A. Levy, Joan T. Merrill, Holly Quasny, David A. Roth, William Stohl, Ronald van Vollenhoven, Daniel J. Wallace, Michelle Petri

Publikováno v: Urowitz, M B, Aranow, C, Asukai, Y, Bass, D L, Bruce, I N, Chauhan, D, Dall'Era, M, Furie, R, Fox, N L, Gilbride, J A, Hammer, A, Ginzler, E M, Gonzalez-Rivera, T, Levy, R A, Merrill, J T, Quasny, H, Roth, D A, Stohl, W, van Vollenhoven, R, Wallace, D J & Petri, M 2022, ' Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus ', Arthritis Care and Research, vol. 74, no. 11, pp. 1822-1828 . https://doi.org/10.1002/acr.24901

Organ damage is a key determinant of poor long-term prognosis and early death in patients with systemic lupus erythematosus (SLE). Prevention of damage is a key treatment goal of the 2019 update of the European Alliance of Associations for Rheumatolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c81a899c9b46ed97a967794594c7bb5
http://www.scopus.com/inward/record.url?scp=85135523522&partnerID=8YFLogxK

Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus

Autor: Ellen, Ginzler, Luiz Sergio, Guedes Barbosa, David, D'Cruz, Richard, Furie, Kathleen, Maksimowicz-McKinnon, James, Oates, Mittermayer Barreto, Santiago, Amit, Saxena, Saira, Sheikh, Damon L, Bass, Susan W, Burriss, Jennifer A, Gilbride, James G, Groark, Michelle, Miller, Amy, Pierce, David A, Roth, Beulah, Ji

Publikováno v: Arthritisrheumatology (Hoboken, N.J.). 74(1)

Enrollment of patients of Black African ancestry with systemic lupus erythematosus (SLE) in phase II and phase III of the belimumab trials was not reflective of the racial distribution observed in the lupus population. This study was undertaken to as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::84e1dc5f0fc4e29954ab82e9ab1f36c8
https://pubmed.ncbi.nlm.nih.gov/34164944